Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma

A 57‐year‐old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptom...

Descripción completa

Detalles Bibliográficos
Autor principal: Wang, Hongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668510/
https://www.ncbi.nlm.nih.gov/pubmed/28892250
http://dx.doi.org/10.1111/1759-7714.12506
_version_ 1783275687460732928
author Wang, Hongmei
author_facet Wang, Hongmei
author_sort Wang, Hongmei
collection PubMed
description A 57‐year‐old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantly relieved. Treatment with apatinib mesylate represents a novel method of treatment for tracheal adenoid cystic carcinoma.
format Online
Article
Text
id pubmed-5668510
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-56685102017-11-09 Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma Wang, Hongmei Thorac Cancer Case Reports A 57‐year‐old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantly relieved. Treatment with apatinib mesylate represents a novel method of treatment for tracheal adenoid cystic carcinoma. John Wiley & Sons Australia, Ltd 2017-09-11 2017-11 /pmc/articles/PMC5668510/ /pubmed/28892250 http://dx.doi.org/10.1111/1759-7714.12506 Text en © 2017 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Wang, Hongmei
Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma
title Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma
title_full Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma
title_fullStr Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma
title_full_unstemmed Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma
title_short Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma
title_sort case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668510/
https://www.ncbi.nlm.nih.gov/pubmed/28892250
http://dx.doi.org/10.1111/1759-7714.12506
work_keys_str_mv AT wanghongmei casereportofapatinibmesylatetreatmentinrareadvancedtrachealadenoidcysticcarcinoma

Ejemplares similares